Peter Attia· MD
In the REDUCE-IT study, EPA triglycerides were lowered 15% maybe you know it was not a huge drop in triglycerides by any means what was the reduction in LDL C&A poby I don't recall yeah virtually no change
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
In the REDUCE-IT study, EPA triglycerides were lowered 15% maybe you know it was not a huge drop in triglycerides by any means what was the reduction in LDL C&A poby I don't recall yeah virtually no change
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the study was called to reduce it which was an acronym as they all are for for something reduce it was the name of the study the product was called vicita like vascular EPA the ASC EPA a company that makes the drugs called Ameren and the way the study was done they gave four grams a day of this EPA it's EPA ethyl ester so it's a very purified EPA that has a FL ester which is the typical way that they used they concentrate omega-3 years nowadays four grams a day versus the four grams of a mineral oil placebo which has had some controversy as to whether that's a real placebo or not roughly 8,000 patients who all were on statin drugs to control their cholesterol levels and they all still had triglycerides between two and five hundred roughly 150 to 500 so triglycerides were still elevated even though they were on a statin cholesterol LDL cholesterol was roughly in the 70s so there was low healthy levels of LDL they also had to have either a history of heart disease or some other risk factors and like having diabetes for example was another way you could get in so if you met that criteria that kind of patient you were given either four grams of placebo or four grams of VAS SEPA
the study had one flaw and i don't know if it's a fatal flaw or not i think that's that needs to be figured out the placebo in that arm was not your typical placebo so typically when you do omega-3 or fatty acid intervention trials the most common placebo is corn oil soybean oil and in this case so they used mineral oil and they were criticized at the time of publication whether epa indeed reduced cardiovascular events or did mineral oil increase cardiovascular events